Valuation: Endonovo Therapeutics Inc

Market Cap 2.77M 2.43M 2.24M 2.07M 3.94M 263M 4M 26.82M 10.43M 130M 10.41M 10.19M 449M P/E 2021
-0.3x
P/E 2022 -0.14x
Enterprise Value 9.93M 8.69M 8.01M 7.42M 14.09M 942M 14.31M 95.99M 37.33M 465M 37.27M 36.46M 1.61B EV / Sales 2021
112,421,804x
EV / Sales 2022 78,689,579x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 61 29/02/2012
Investor Relations Contact - 30/04/2014
Corporate Officer/Principal 70 28/02/2022
Director TitleAgeSince
Chairman 61 29/02/2012
Change 5-day change 1-year change 3-year change Capi.($)
-0.10%+0.10%+74.33%+133.26% 57.73B
-3.80%-6.24%+67.04%+86.36% 54.69B
+0.30%+1.56%-14.13%-11.56% 23.75B
+0.95%+6.25%+16.84%+470.39% 24.18B
-2.70%+4.25%+40.38%-3.72% 19.82B
+3.78%+5.65%+44.99%-26.23% 17.14B
+3.46%+17.72%+206.66%+364.07% 16.75B
-1.81%+18.00%+41.99% - 15.57B
+2.28%+4.47%+28.71%+194.36% 13.96B
Average +0.26%+5.56%+56.31%+150.86% 27.06B
Weighted average by Cap. -0.46%+3.34%+57.96%+139.48%

Financials

2021 2022
Net sales 0.07 0.06 0.06 0.05 0.1 6.94 0.11 0.71 0.27 3.42 0.27 0.27 11.84 0.14 0.12 0.11 0.1 0.19 12.85 0.2 1.31 0.51 6.34 0.51 0.5 21.91
Net income -3.1M -2.72M -2.5M -2.32M -4.41M -295M -4.48M -30.03M -11.68M -145M -11.66M -11.4M -503M -18.47M -16.17M -14.9M -13.81M -26.22M -1.75B -26.64M -179M -69.48M -865M -69.36M -67.86M -2.99B
Net Debt 7.1M 6.21M 5.72M 5.3M 10.07M 673M 10.23M 68.61M 26.68M 332M 26.64M 26.06M 1.15B 7.15M 6.26M 5.77M 5.35M 10.15M 679M 10.31M 69.17M 26.9M 335M 26.86M 26.27M 1.16B
Logo Endonovo Therapeutics Inc
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at approximately 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.
Employees
-